Severe Locked-In-Like Guillain-Barré's Syndrome: Dilemmas in Diagnosis and Treatment

Rudolf Korinthenberg1, Matthias Eckenweiler1, Hans Fuchs2

  • 1Department of Neuropediatrics and Muscular Disorders, Faculty of Medicine, University Medical Center, University of Freiburg, Freiburg, Germany.

Neuropediatrics
|October 28, 2020
PubMed

Insights

This case study highlights a severe childhood Guillain-Barré syndrome (GBS) with a locked-in-like state. Repeated immunomodulatory treatment led to significant functional recovery, challenging typical GBS treatment protocols.

Area of Science:

  • Pediatric Neurology
  • Neuroimmunology
  • Clinical Case Studies

Background:

  • Childhood Guillain-Barré syndrome (GBS) presents diagnostic and therapeutic challenges due to atypical disease courses.
  • Early and intensive immunomodulatory treatment is standard for severe GBS.
  • Protracted and severe GBS can mimic other neurological conditions, complicating management.

Observation:

  • A 13-year-old boy developed acute GBS, progressing over 40 days to a severe locked-in-like syndrome despite initial immunomodulatory therapy.
  • The patient experienced a 3-month plateau phase with fluctuating inflammatory activity.
  • Atypical features at onset and profound neurological deficits were noted.

Findings:

  • Repeated and maintenance immunomodulatory treatment was initiated due to persistent inflammatory signs.
  • This delayed treatment strategy resulted in continuous and near-complete functional recovery.
  • The case demonstrates a late but substantial response to prolonged immunomodulatory intervention.

Implications:

  • This case underscores the need to consider atypical presentations and protracted courses in childhood GBS.
  • It suggests that prolonged or repeated immunomodulatory treatment may be beneficial in severe, refractory GBS cases.
  • Revisiting diagnostic and therapeutic dilemmas in severe, atypical GBS is crucial for optimizing patient outcomes.

Related Concept Videos

Myasthenia Gravis: Diagnostic Tests01:15

Myasthenia Gravis: Diagnostic Tests

Myasthenia gravis is an autoimmune condition affecting neuromuscular transmission, causing generalized weakness in skeletal muscles. Initial diagnoses rely on patients' signs, symptoms, and medical history. The challenge lies in distinguishing myasthenia from other muscular dystrophies. An important diagnostic feature is the significant improvement of symptoms after administering anticholinesterase inhibitors.
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
1.7K
Myasthenia Gravis: Overview and Treatment01:20

Myasthenia Gravis: Overview and Treatment

Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
2.5K
Depolarizing Blockers: Pharmocokinetics01:19

Depolarizing Blockers: Pharmocokinetics

Depolarizing blockers are administered through intravenous injection. Succinylcholine is the most common choice of depolarizing blockers in emergency clinical practices. Although they have a rapid onset, they readily diffuse away from the motor end plate into the extracellular fluid. They are metabolized by enzymes such as liver butyrylcholinesterase and plasma pseudocholinesterases. This produces a short duration of action, typically 5-10 minutes long, unlike nondepolarizing blockers, which...
490